Acea Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
Phase 1
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: AC0058TADrug: Placebo AC0058TA
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- ACEA Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03878303
- Locations
- 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
Study of AC0058TA in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AC0058TADrug: Placebo capsules
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- ACEA Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02847325
- Locations
- 🇺🇸
Covance Clinical Development Services, Dallas, Texas, United States
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- ACEA Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02448251
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
News
No news found